Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 115 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 1 Blinded - Placebo Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

NCT07133828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB142, BIIB142-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Results available

Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop

NCT02328040
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo and Insulin monotherapy via CL, Sitagliptin and insulin/novolog via CL
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
14 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 24, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

NCT06311656
View directory record Official record
Conditions
Healthy
Interventions
LY4100511 (DC-853), Placebo
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

NCT02007512
View directory record Official record
Conditions
Breast Cancer
Interventions
Enzalutamide, exemestane, Placebo (for enzalutamide)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
89
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

NCT01240980
View directory record Official record
Conditions
Diabetes
Interventions
BMS-903452, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Eltrombopag at Escalated Doses

NCT01880047
View directory record Official record
Conditions
Immune Thrombocytopenia, Platelet Disorder
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

NCT02045940
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

NCT02435173
View directory record Official record
Conditions
Common Variable Immunodeficiency (CVID), APDS / PASLI
Interventions
CDZ173, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

NCT05085561
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
REC-994, Placebo
Drug
Lead sponsor
Recursion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067
View directory record Official record
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

NCT04880031
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
48
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Research Study Investigating Mim8 in People With Haemophilia A

NCT04204408
View directory record Official record
Conditions
Healthy Volunteers, Haemophilia A With or Without Inhibitors
Interventions
NNC0365-3769 (Mim8), Placebo (Mim8)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 24, 2026, 1:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

NCT04066491
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions
M7824, Placebo, Gemcitabine, Cisplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

NCT03654313
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
MEDI6570, Placebo, Part B Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Anniston, Alabama • Jacksonville, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 24, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase1 Study of VIB9600

NCT03621605
View directory record Official record
Conditions
Safety Issues
Interventions
VIB9600, Placebos
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Study of ST266 Versus Saline in Treating Skin Irritation From Radiation

NCT01714973
View directory record Official record
Conditions
Radiation-induced Dermatitis
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Lenacapavir, Placebo, B/F/TAF, TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Sacramento, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 24, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

NCT03516487
View directory record Official record
Conditions
Phenylketonuria, Healthy
Interventions
SYNB1618, Placebo
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 24, 2026, 1:38 PM EDT